Human bone marrow-derived stromal stem cells (hMSC) (also known as skeletal stem cells, mesenchymal stem cells) are a group of clonogenic cells that are present among the bone marrow stroma as well as the stroma of other organs. hMSC are capable of multilineage differentiation into mesoderm-type cells such as osteoblasts, adipocytes and chondrocytes[@b1-asm-1-68] and possibly, but still controversially, non-mesoderm type cells like neuronal cells or hepatocytes.[@b2-asm-1-68],[@b3-asm-1-68] Moreover, hMSC provide supportive stroma for growth and differentiation of hematopoeitic stem cells (HSC) and hematopoiesis.[@b4-asm-1-68] Recently, MSC has been employed in an increasing number of cell-based therapies for treating skeletal and non-skeletal chronic degenerative diseases. The aim of this review is to provide an update on the biology of hMSC and their current and potential uses in therapy.

Biological characteristics of hMSC
==================================

hMSC are fusiform, fibroblast-like cells that form colonies when cultured at a low density[@b5-asm-1-68]--[@b7-asm-1-68] ([Figure 1](#f1-asm-1-68){ref-type="fig"}). hMSC exhibit characteristic surface markers being negative for hematopoietic cell markers: CD34−, CD45−, CD14− and positive for CD29+, CD73+, CD90+, CD105+, CD166+ and CD44+.[@b8-asm-1-68]--[@b10-asm-1-68] Unfortunately, these markers are not specific for MSC and are expressed in a number of other mesodermal cells. Therefore, MSC are usually defined operationally as cells capable of ex vivo differentiation to osteoblastic, adipocytic and chondrocytic cells (i.e. multipotential) or forming bone and bone marrow organ--- "an ossicle" upon transplantation subcutaneously in immune-deficient mice ([Figure 2a](#f2-asm-1-68){ref-type="fig"}).[@b11-asm-1-68] Traditionally, MSC have been isolated from bone marrow low-density mononuclear cell populations based on their selective adherence to plastic surfaces ([Figure 1](#f1-asm-1-68){ref-type="fig"}).[@b7-asm-1-68],[@b12-asm-1-68],[@b13-asm-1-68] hMSC have also been isolated using antibody-based cell selection employing a number of antibodies (e.g. Stro-1,[@b14-asm-1-68],[@b15-asm-1-68] CD146 (MCAM),[@b16-asm-1-68] CD200 and CD271).[@b17-asm-1-68], [@b18-asm-1-68]

Other MSC-like cells obtained from different tissues
====================================================

Populations with MSC-like phenotype have been isolated from different tissues including peripheral blood,[@b19-asm-1-68] umbilical cord blood,[@b20-asm-1-68] synovial membranes,[@b21-asm-1-68] adipose tissue,[@b22-asm-1-68] lung,[@b23-asm-1-68] fetal liver,[@b24-asm-1-68] dental pulp[@b25-asm-1-68],[@b26-asm-1-68] and deciduous teeth.[@b27-asm-1-68] In particular adipose tissue-derived MSC cultured from fat tissue aspirates obtained during liposuction procedures represent a good source for obtaining large number of hMSC.[@b28-asm-1-68] Tissue-specific MSC share some basic morphological and differentiation characteristics with bone marrow-derived MSC. However, these cells are not identical and differences have been reported in their "genetic signature" as determined by global analysis of their transcriptomes.[@b29-asm-1-68]--[@b31-asm-1-68]

From the laboratory to the clinic
=================================

The emerging field of regenerative medicine holds promise for treating a variety of degenerative and age-related diseases, where no specific or effective treatment is currently available, by transplanting biologically competent mature cells and tissues or by stimulating tissue-resident stem cells. Stem cells in general and MSC in particular with their versatile growth and differentiation potential, are ideal candidates for use in regenerative medicine protocols and are currently making their way into clinical trials. However, successful use of MSC in therapy requires developing well-defined methods for MSC cell isolation, growth and differentiation. The following sections cover progress achieved in understanding the biology of MSC relevant for their clinical use.

Isolation of hMSC prospectively based on specific criteria
==========================================================

The current standard procedure for isolating hMSC based on plastic adherence to cell culture plates, results in heterogeneous cell cultures comprised of MSC and other tissue specific cells. Thus, there is a need for identifying surface markers that can be employed in isolating hMSC prospectively. We have employed several approaches to identify hMSC-specific markers. Using DNA microarray technology, we have identified a set of genes (a molecular signature) predictive for "stemness" phenotype as evaluated by in vivo criteria. [@b32-asm-1-68] We have also employed state-of-the-art mass spectrometry-based proteomic methods to identify novel plasma membrane-associated protein makers.[@b33-asm-1-68] These global methods provide a large number of novel candidate marker genes and proteins that are currently being verified and tested for their usefulness in isolating homogenous populations of hMSC needed for clinical applications.

Limited in vitro cell growth and replicative senescence of hMSC
===============================================================

The clinical use of hMSC requires the availability of a large number of functionally competent cells with a stable phenotype and genotype. This is usually achieved by long-term ex vivo culturing of hMSC. However, hMSC, in contrast to embryonic stem cells or cancer cells, exhibit a limited capacity for ex vivo growth, a phenomenon known as "in vitro replicative senescence".[@b34-asm-1-68] Also, the proliferative capacity of hMSC is dependent on donor age and thus compromises the ability to generate enough number of cells from elderly donors.[@b34-asm-1-68] Several approaches have been tried to improve ex vivo growth of hMSC using an enriched culture media with the addition of relevant growth factors, e.g. fibroblast growth factor 2 (FGF-2).[@b35-asm-1-68] We have also demonstrated that genetic over-expression of human telomerase reverse transcriptase gene (hTERT) in hMSC increases their telomerase activity and abolishes replicative senescence phenotype.[@b36-asm-1-68] However, genetic manipulation of hMSC is not desirable for cells to be used in clinical transplantation and alternative methods for ex vivo enhancement of hMSC growth, e.g. use of small chemical molecules with proliferation-enhancing abilities or a enhancing cell growth by using a combination of growth factors represent alternative approaches that are being tested.

Directing differentiation of MSC into specific lineages
=======================================================

While the multi-potentiality of MSC is the basis for using the cells for generating differentiated cells for cell replacement therapy, protocols that direct the differentiation of hMSC into a specific lineage are still inefficient and require improvement. Several approaches have been employed to direct the differentiation of MSC to a particular lineage. For example, differentiation into bone-forming osteoblastic cells has been achieved as ex vivo treatment with a mixture of growth factors (e.g. bone morphogenetic protein \[BMP\] or transforming growth factor \[TGF\]-β) to enhance osteoblast differentiation.[@b37-asm-1-68],[@b38-asm-1-68]

Development of "off-the-shelf" MSC for allogeneic transplantation
=================================================================

Our current experience with autologus hMSC transplantation in clinical trials shows that it does not result in immunological problems. However, allogeneic hMSC transplantation is more clinically relevant since it allows the development of "off-the-shelf " allogeneic cells ready for use in therapy. hMSC are hypoimmunogenic and thus allogeneic hMSC transplantation may be possible. hMSC express intermediate levels of HLA major histocompatibility complex (MHC) class I molecules, low levels of HLA class II antigens and no expression of co-stimulatory molecules e.g. CD40, CD40L, CD80 or CD86.[@b39-asm-1-68],[@b40-asm-1-68] Also, MSC have been reported to possess immunosuppressive properties in vitro as they inhibit T-cell alloreactivity induced in mixed lymphocyte cultures or by nonspecific factors.[@b41-asm-1-68],[@b42-asm-1-68] In addition, MSC inhibit the secretion of TNF-β and IL-10 secretion by dendritic cells and therefore directs the immune response toward more anti-inflammatory/tolerant phenotype.[@b43-asm-1-68] In vivo, the immunosuppressive effect of MSC has been shown by their ability to prolong histo-incompatible skin graft survival.[@b44-asm-1-68] These immunoregulatory characteristics are the basis of using hMSC in the treatment of graf-versus-host (GvH) disease.

Is it safe to transplant hMSC?
==============================

There are concerns that transplanted, culture-expanded hMSC may undergo spontaneous transformation and lead to cancer.[@b45-asm-1-68] The concept of the transformation potential of MSC is based mainly on extrapolations from studies performed on murine MSCs that exhibit spontaneous malignant transformation in long-term culture. However, spontaneous transformation of cultured hMSC has not been reported. Although Rubio et al[@b46-asm-1-68] reported that cultured adipose-tissue derived MSC from children exhibited spontaneous transformation in long-term culture, the results of this study were later shown to be false and caused by spurious contamination with an osteosarcoma cell line cultured simultaneously in the lab.[@b47-asm-1-68],[@b48-asm-1-68] Another area of concern is the possible role of administered hMSC in promoting growth of a latent tumor. Some studies have demonstrated that MSC can be recruited to the stroma of developing tumors when systemically infused in animal models for glioma, colon carcinoma, ovarian carcinoma, Karposi sarcoma, and melanoma.[@b49-asm-1-68] Conversely, the current clinical experience with hMSC transplantation, though limited, has been safe with an absence of cancer transformation. In conclusion, human MSC obtained from healthy individuals do not readily transform in culture and are safe for transplantation. However, further studies are needed to develop a set of safety criteria for predicting normal behavior of MSC employed in clinical programs.

What is the mechanism of tissue repair achieved by hMSC?
========================================================

It has been thought that the therapeutic potential of hMSC is based on their ability to differentiate into a particular lineage cells that replace damaged cells and contribute to tissue regeneration. However, recent studies suggest that important therapeutic effects of MSC are mediated by their secreted factors (i.e. paracrine effects). [@b50-asm-1-68],[@b51-asm-1-68] This mechanism may explain the intriguing observation of the presence of therapeutically-relevant effects after systemic or local transplantation of hMSC in a number of animal models of tissue injury (e.g. myocardial infarction, ischemic brain injury, in spite of the presence of low tissue engraftment). Several putative secreted factors with anti-inflammatory, anti-apoptotic and immune-modulatory effects are known to be produced by MSC.[@b51-asm-1-68]--[@b53-asm-1-68] Identifying novel regeneration-promoting factors produced by MSC suitable for clinical use, is currently an active area of research in several laboratories.

Clinical application of hMSC in tissue regeneration
===================================================

hMSC have been employed in an increasing number of clinical trials that range from individual case reports, patient series, and non-randomized as well as randomized clinical trials n skeletal and non-skeletal tissue regeneration. [Tables 1](#t1-asm-1-68){ref-type="table"} and [2](#t2-asm-1-68){ref-type="table"} are a list of clinical trials in which hMSC have been employed. In the website of the National Institutes of Health, USA (<http://clinicaltrials.gov>), approximately 95 clinical trials are registered and covers a diverse indication (e.g. bone diseases, cardiovascular diseases and other rare pathologies such as amyotrophic lateral sclerosis (ALS), Hurler syndrome and metachromatic leukodystrophy). Results from these clinical trials are expected to have a major impact on the treatment of several disease conditions ([Figure 3](#f3-asm-1-68){ref-type="fig"}).

Use of hMSC for skeletal tissue regeneration and non-skeletal repair and regeneration
=====================================================================================

hMSC possess the ability for osteoblast and chondrocyte differentiation and thus can potentially be used in skeletal tissue regeneration. Several animal studies have demonstrated the efficacy of MSC in treatment of segmental bone defects in rat and sheep where autologous bone marrow--derived MSCs were expanded in culture, then injected directly at the site of injury or after loading onto synthetic or natural biomaterial (i.e. scaffold).[@b54-asm-1-68]--[@b56-asm-1-68] Human clinical case reports have demonstrated the success of autologus MSC in the treatment of large bone defects in patients with defective fracture healing[@b57-asm-1-68]--[@b60-asm-1-68] and cartilage defects.[@b61-asm-1-68]--[@b63-asm-1-68] In a recent study of atrophic tibial diaphyseal nonunion fractures, percutaneous autologous bone marrow stem cells were injected into[@b60-asm-1-68] atrophic non-union fractures of the tibia and the investigators reported positive effects that were correlated with the number of implanted hMSC.[@b64-asm-1-68] Also, promising preliminary results for treatment of femoral head osteonecrosis have been reported.[@b65-asm-1-68],[@b66-asm-1-68] [Table 1](#t1-asm-1-68){ref-type="table"} summarizes some of clinical trials using hMSC for bone regeneration. A number of clinical trials where hMSC has been employed for enhancing non-skeletal repair and are summarized in [Table 2](#t2-asm-1-68){ref-type="table"} and [Figure 3](#f3-asm-1-68){ref-type="fig"}. Both autologous and allogeneic MSC have been employed.

Graft-versus-host disease (GvHD) disease
========================================

GvHD is a potentially fatal disease that develops in the context of allogenic hematopoietic stem cell transplantation. In a pilot study, MSC was employed to treat 9 patients (8 patients with steroid refractory acute GvHD and 1 patient with chronic GvHD) where hMSC obtained from a 2 HLA identical sibling, 5 haploidentical donor and 4 HLA-mismatched donors, and resulted in the clinical recovery in 6 of the 8 patients.[@b67-asm-1-68] The beneficial effects of autologous hMSC transplantation have been also observed in a phase II clinical trial of 55 children and adult patients with acute severe and steroid resistant GvHD. Infusion of MSC was safe, and resulted in higher survival rates in patients with complete response (54.5%) and significantly lower transplantation-related mortality in patients with partial or no response (45.5%).[@b68-asm-1-68] In a recent randomized clinical trial of 32 patients with grade II--IV GvHD that either received intravenous autologous MSC (2 or 8 million MSCs/kg) or standard therapy, 77% of patients exhibited complete response and no MSC infusion-related toxicities were observed.[@b69-asm-1-68] In addition to using BM-derived MSC, Fang et al. also reported some success using human adipose tissue-derived hMSC for treatment of steroid-refractory GvHD.[@b70-asm-1-68],[@b71-asm-1-68] Currently several phase II and III clinical trials are being conducted to confirm these encouraging initial results and to define the role of MSC transplantation as either the primary therapy or as adjuvant therapy.

Heart diseases
==============

MSC transplantation for enhancing myocardial tissue regeneration following acute myocardial infarction or chronic ischemic heart failure is an important area of regenerative medicine and has been initiated based on the positive therapeutic effects of marrow-derived MSC demonstrated in preclinical animal models.[@b72-asm-1-68]--[@b75-asm-1-68] For example, in a porcine myocardial infarction (MI) model, bone-marrow derived MSCs injected directly into the myocardium were found to efficiently engraft into the myocardium and to significantly reduce infarct size, wall thinning, and contractile dysfunction.[@b72-asm-1-68] In humans, a placebo-controlled clinical study of intra-coronary injection of autologous MSC in 69 patients with acute myocardial infarction where MSC was injured within 12 hours after the onset of symptoms. No side effects or toxicity were reported during the 6-month follow-up and beneficial effects of increased left ventricular ejection fraction and Left ventricular end diastolic volume, improved contractility and enhanced infarct viability were reported.[@b76-asm-1-68] In a recent study, Hera et al performed a double-blind, placebo-controlled, dose-ranging (0.5, 1.6, and 5 million hMSC cells per kg) safety trial of intravenous allogeneic hMSCs conducted in 53 patients with anterior myocardial infarction with a follow up period of 6 months. No side effects of therapy were observed and global symptom score and ejection fraction (an estimated of left ventricular function) were significantly improved in the hMSC-treated group compared to controls.[@b77-asm-1-68] Results from these initial studies are encouraging and demonstrate the need for confirmation in larger randomized clinical trials.

Neurological diseases
=====================

Preclinical studies have demonstrated the importance of post-injury neurogenesis for clinical recovery in animal models of stroke and that local transplantation of MSCs enhanced this process.[@b78-asm-1-68]--[@b80-asm-1-68] A recent study in rats has demonstrated the beneficial effects of administering allogenic MSC during the acute phase of ischemic stroke in improving neurological recovery and decreasing brain damage. The beneficial effects have been reported to be obtained regardless of the administration route (intravenous or intracarotid).[@b78-asm-1-68] Recently, the results of an open-label, observer blinded clinical trial in 52 patients with severe middle cerebral artery territory infarct have been reported. Patients were randomly allocated to receive intravenous autologous ex vivo cultured MSC (5×10^7^ cells/patient) (MSC group) or standard therapy (control group) and both groups were followed for 5 years. The mortality rate in the MSC-treated group was lower and some improvement in the functional recovery in MSC-treated group was observed.[@b81-asm-1-68]

The use of MSC in therapy has been reported in a few other neurological diseases. Multiple system atrophy (MSA) is a sporadic, progressive, adult-onset neurodegenerative disorder associated with varying degrees of symptoms of Parkinsonism, autonomic dysfunction, and cerebellar ataxia with no available drug treatment. Lee et al evaluated the feasibility and safety of therapy of autologous MSC infusion in 29 patients with MSA and reported that MSC transplantation delayed the progression of neurological deficits as well as significantly greater functional improvement in the MSC-treated patients and with no serious adverse effects related to MSC therapy.[@b82-asm-1-68]

Renal diseases
==============

As mentioned above, the anti-inflammatory effects of transplanted MSC may offer a novel therapeutic strategy in acute and chronic kidney disease and also for treatment of renal allograft rejection.[@b83-asm-1-68] In pre-clinical studies, the beneficial effects of MSC infusion on repair of acute renal damage have been reported. In an acute renal failure (ARF) mouse model, injection of allogeneic BM-derived MSCs protected cisplatin-treated mice from renal function impairment and severe tubular injury. Donor cells were shown to localize within the tubular epithelial lining suggesting that MSC engrafted within the damaged kidney.[@b84-asm-1-68] Lange et al[@b85-asm-1-68] reported that in a rat ARF model, MSC-treated animals had both significantly better renal functions and lower injury scores. The specificity of MSC effects were studied by Togel et al[@b86-asm-1-68] in rats with ischemia-reperfusion-induced acute renal failure. The authors reported that intra-carotid artery administration of MSC after the onset of renal ischemia resulted in significantly improved renal functions compared with animals treated with fibroblasts. Also, preliminary results of a phase I clinical trial of autologous MSC in 5 patients with post operative acute kidney injury (AKI) have shown that administration of autologous MSC was safe and some beneficial effects as renal function was well preserved postoperatively and none of the patients required hemodialysis.[@b87-asm-1-68]

Other diseases
==============

Systemic lupus erythromatosis (SLE) is a systemic multi-organ autoimmune disease that involves the cardiovascular system, joints and kidneys. The pathogenesis of SLE has been attributed to T cell deficiencies, polyclonal B-cell activation, macrophage dysfunction and environmental factors such as hormonal disturbances. [@b88-asm-1-68] Also, defects in hematopoietic stem cells have been suggested as a pathological mechanism underlying SLE.[@b89-asm-1-68] The effects of allogeneic intravenous infusion of umbilical cord-derived MSC (1×10^6^ cells/kg body weight) in 15 patients with SLE patients has been recently published and demonstrated safety, improvement of clinical symptoms and stabilization of inflammatory markers.[@b90-asm-1-68]

Another inflammatory condition where MSC has been employed is Crohn disease. Results of a phase II randomized controlled trial in patients with Crohn disease-related perianal fistulas refractory to conventional therapies have been reported.[@b91-asm-1-68] Intravenous (2×10^7^ cells) autologous adipose-tissue derived and expanded MSCs were given to 24 patients along with fibrin glue (FG) and the effects were compared to 25 control patients that received FG alone. The administration of MSC in combination with FG was not associated with any side effects and was associated higher rates of healing. MSC have been tried for treatment of recto-vaginal fistula in a recent case report.[@b92-asm-1-68]

Uncontrolled and commercial stem cell therapy (stem cell tourism)
=================================================================

The enthusiastic media coverage of recent developments in stem cell biology and the positive initial results of stem cell-based clinical trials, have created unrealistic public understanding of the nature of the available stem cell therapies. Many patients and their families think that it is possible to treat a large number of chronic degenerative diseases using stem cells. The situation became complicated due to the wide use of the internet as a source for medical information and the establishment of several commercial companies that offer uncontrolled stem cell therapies. These companies employ stem cells from a wide variety of sources, including embryonic stem cells, and they claim that stem cells can be employed to treat all diseases! These commercial companies usually provide therapy that is very expensive and without any proof for efficacy. As mentioned above, stem cell therapy for chronic degenerative conditions is experimental therapy and should not be provided outside clinical trials in academic institutions. Patients should be discouraged from receiving stem cell therapies from commercial companies. The International Stem Cell Research Society (ISCRS) has responded to the increasing demands for objective information and guidance regarding stem cell therapy by publishing a guide to patients and their families (please see: <http://www.isscr.org/clinical_trans/patient_handbook.html>).

Conclusions and future perspectives
===================================

The potential for MSC use in therapy is enormous and positive results have been obtained in preclinical animal models of human diseases and from phase I/II clinical trials with very promising preliminary results. We think that combining basic research studies identifying the mechanisms controlling of MSC cell proliferation and differentiation with well designed and controlled clinical trials, will bring major advances in realizing the potential of MSC-based therapy for treatment of chronic and degenerative diseases.
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![Standard isolation procedure for bone marrow derived human stromal (mesenchymal) stem cells (MSC). The cells are established in cultures based on their characteristic plastic surface adherence ability.](asm-1-68f1){#f1-asm-1-68}

![Multipotentiality of human stromal (mesenchymal) stem cells (MSC). Under proper conditions, MSCs can form (a) bone when implanted subcutaneously in immune deficient mouse coupled with hydroxyapatite/tricalicum phosphate (HA/TCP) as carrier, (b) cartilage when cells cultured in vitro as cell aggregates in presence of transforming growth factor B or (c) fat when treated in vitro with insulin, dexamethasone and rosiglitazone.](asm-1-68f2){#f2-asm-1-68}

![Examples of ongoing or completed clinical trials using stromal stem cell. Data were collected from National Institute of Health (NIH), USA, clinical trials registery on (March 2011). Categorization was based on information provided in the trial summary.](asm-1-68f3){#f3-asm-1-68}

###### 

Examples of published clinical trials using human stromal stem cell therapy in skeletal disorders.

  System                 Indication                                                    Sample size   Cell type                                                                                                Study design              Delivery route          Outcome                                                                                                                                                                                                                                                                                Ref
  ---------- ----------- ------------------------------------------------------------- ------------- -------------------------------------------------------------------------------------------------------- ------------------------- ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  Skeletal   Bone        Tibial non-union fracrure                                     20            Autologous bone marrow                                                                                   Prospective study         Percutanous injection   Clinical and radiological bone union following in 15 out of 20 patients                                                                                                                                                                                                                [@b57-asm-1-68]
                         Large bone diaphysis defects (tibia, ulna, humerus)           4             Autologous MSC's cultured and seeded on porous hydroxyapatite scaffold                                   Case report               Local implantation      Complete fusion between the implant and the host bone occurred 5 to 7 months after surgery. In all patients at the last follow-up (6 to 7 years post surgery), a good integration of the implants was maintained                                                                       [@b58-asm-1-68]
                         Atrophic tibial diaphysea non-union sites                     60            Autologous bone marrow                                                                                   Prospective study         Percutanous injection   Bone unions were obtained in 53 patients after 6 months.                                                                                                                                                                                                                               [@b64-asm-1-68]
                         Steroid-induced osteonecrosis of the femoral head             3             Autologous MSC's cultured with beta-tricalcium phosphate                                                 Case report               Intrafemoral            Osteonecrosis did not progress and early bone regeneration was observed.                                                                                                                                                                                                               [@b65-asm-1-68]
                         Femoral head osteonecrosis                                    13            Autologous bone marrow                                                                                   Phase I clinical trialI   ntrafemoral injection   Significant reduction in pain and in joint symptoms within the bone-marrow-graft group At twenty-four months, five of the eight hips in the control group had deteriorated to stage III, whereas only one of the ten hips in the bone-marrowgraft group had progressed to this stage   [@b66-asm-1-68]
                         Unicameral bone cysts                                         79            Bone marrow                                                                                              Clinical trial            Intra cystic            No clear differences in healing compared with steroid injection                                                                                                                                                                                                                        [@b93-asm-1-68]
                         Mandibular defect                                             1             Autologous bone marrow seeded on titanium mesh cage scaffold filled with bone mineral blocks and BMP 7   Case report               Local implantation      In-vivo skeletal scintigraphy showed bone remodelling and mineralisation inside the mandibular transplant both before and after transplantation. CT provided radiological evidence of new bone formation.                                                                              [@b94-asm-1-68]
             Cartilage   Full-thickness articular cartilage defects in human patella   2             Autologous bone marrow stromal cells                                                                     Case report               Local implantation      Evidence for promotion of repair of articular cartilage defects                                                                                                                                                                                                                        [@b61-asm-1-68]
                         Achondroplasia, congenital pseudarthrosis                     3             Autologous MSC's mixed with platelet rich plasma                                                         Case report               Local injection         Acceleration of bone regeneration during distraction osteogenesis                                                                                                                                                                                                                      [@b62-asm-1-68]

###### 

Examples of published clinical trials using human stromal stem cell therapy in non-skeletal disorders.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  System                                 Indication                              Sample size   Cell type                        Study design                           Delivery route        Outcome                                                                                                                                        Ref
  ------------------ ------------------- --------------------------------------- ------------- -------------------------------- -------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  Non-Skeletal       Cardiovascular      Acute myocardial infarction             34\\35        Allogenic MSCs                   Placebo controlled clinical trial      Intracoronary         Increased left ventricular ejection fraction and left ventricular end diastolic volume, improve contractility and enhanced infarct viability   [@b76-asm-1-68]

                                         Acute myocardial infarction             53            Allogenic MSCs (Prochymal)       Double-blind, placebo-controlled       Intravenous           Significant improvement of ejection fraction in hMSC-treated group                                                                             [@b77-asm-1-68]

                     Nephrology          Acute kidney injury (post-operative)    15            Autologous MSCs                  Phase 1 Trial                          Intraarterial         Renal function was well preserved postoperatively, and none of the patients required hemodialysis.                                             [@b87-asm-1-68]

                     Gastro-intestinal   Perianal fistulas (Crohn disease)       24\\25        Allogenic adiposetissue MSCs     Phase II Randomized controlled trial   Intravenous           AD-MSC induced higher rates of healing when used together with fibrin glue compared to fibrin glue alone                                       [@b91-asm-1-68]

                     Neurology           Multiple system atrophy                 11\\18        Autologous MSCs                  case-control study                     Intra-arterial × 1\   Delayed the progression of neurological deficits with achievement of functional improvement                                                    [@b82-asm-1-68]
                                                                                                                                                                       Intravenous ×3                                                                                                                                                       

                                         Stroke                                  16\\36        Autologous MSC                   Randomised, Placebo controlled         Intravenous           Improve recovery after stroke, improvements in the Barthel index and modified Rankin score                                                     [@b81-asm-1-68]

  Multiple systems                       Steroid-resistant, severe, acute GvHD   55            Autologous MSCs                  phase II study                         Intravenous           Better survival in patients with complete response (54.5%)                                                                                     [@b68-asm-1-68]

                                         Acute GvHD                              32            Allogenic MSCs                   Randomized clinical trial              Intravenous           77% of patients fully responded, 17% partially responded                                                                                       [@b69-asm-1-68]

                                         Lupus nephritis                         16            Allogeneic umbilical cord MSCs   Phase I clinical trial                 Intravenous           Improved Systemic activity Index and renal function                                                                                            [@b95-asm-1-68]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GvHD, Graft versus host disease. MSC's, Mesenchymal Stem Cells. SLE, Systemic lupus erythromatosis
